Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

TNFSF11 – Autosomal Recessive Osteopetrosis

Autosomal recessive osteopetrosis (ARO) is characterized by impaired osteoclast differentiation, leading to high bone density and marrow failure. In six unrelated individuals with osteoclast-poor ARO, biallelic mutations in TNFSF11 were identified, and affected bone specimens lacked TRAP-positive osteoclasts (PMID:17632511).

Genetic analysis revealed three distinct variants in TNFSF11: a frameshift c.828_829del (p.Val277fs), a splice-region deletion c.532+4_532+8del, and a missense c.596T>A (p.Met199Lys). All probands were homozygous or compound heterozygous for these alleles, consistent with autosomal recessive inheritance and demonstrating moderate genetic evidence (6 probands; AR segregation) (PMID:17632511).

Functional rescue experiments showed that exogenous recombinant RANKL restored osteoclast formation from patient monocytes in vitro, confirming loss of function of endogenous RANKL (PMID:17632511). A mouse model harboring the analogous Rankl G278R mutation replicates severe osteopetrosis with absent osteoclasts, and RANKL administration rescues bone resorption in vivo (PMID:22068587).

Structural studies of the human M199K variant revealed disrupted trimerization, impaired receptor binding, and reduced protein stability, elucidating the molecular mechanism of RANKL deficiency in ARO (PMID:32964459). These data provide strong functional evidence supporting haploinsufficiency of RANKL in AR osteopetrosis.

Integration of genetic and experimental findings substantiates a definitive mechanistic link between biallelic TNFSF11 variants and osteoclast-poor ARO. While genetic evidence is moderate by count, concordant in vitro rescue and in vivo models elevate the overall clinical validity to Strong.

Key Take-home: TNFSF11 sequencing should be included in AR osteopetrosis panels, and exogenous RANKL represents a potential targeted therapy for RANKL-deficient ARO.

References

  • Nature Genetics • 2007 • Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. PMID:17632511
  • Human Molecular Genetics • 2012 • A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. PMID:22068587
  • Journal of Cellular Physiology • 2021 • A missense mutation sheds light on a novel structure-function relationship of RANKL. PMID:32964459

Evidence Based Scoring (AI generated)

Gene–Disease Association

Strong

Six probands across multiple families with AR inheritance and concordant functional rescue and animal model data

Genetic Evidence

Moderate

Six unrelated probands with biallelic TNFSF11 variants (missense and loss-of-function); autosomal recessive segregation

Functional Evidence

Strong

Exogenous RANKL restores osteoclastogenesis in patient cells (PMID:17632511); Rankl G278R mouse model recapitulates phenotype and is rescued by RANKL (PMID:22068587)